{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:52:49Z","timestamp":1777870369325,"version":"3.51.4"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s40620-020-00951-6","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T05:03:09Z","timestamp":1609563789000},"page":"281-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Far di Necessit\u00e0 Virt\u00f9, using rare tubulopathies, Gitelman\u2019s and Bartter\u2019s syndromes, to inform the fight against COVID-19"],"prefix":"10.1093","volume":"34","author":[{"given":"Lorenzo A.","family":"Cal\u00f2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"key":"951_CR1","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ddr.21656","volume":"81","author":"D Gurwitz","year":"2020","unstructured":"Gurwitz D (2020) Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 81:537\u2013540. https:\/\/doi.org\/10.1002\/ddr.21656","journal-title":"Drug Dev Res"},{"key":"951_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","volume":"17","author":"M Paz Ocaranza","year":"2020","unstructured":"Paz Ocaranza M, Riquelme JA, Garc\u00eda L, Jalil JE, Chiong M, Santos RAS, Lavandero S (2020) Counter-regulatory renin\u2013angiotensin system in cardiovascular disease. Nat Rev Cardiol 17:116\u2013129. https:\/\/doi.org\/10.1038\/s41569-019-0244-8","journal-title":"Nat Rev Cardiol"},{"key":"951_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104736","author":"F Abedi","year":"2020","unstructured":"Abedi F, Hayes AW, Reiter R, Karimi G (2020) Acute lung injury: the therapeutic role of Rho kinase inhibitors. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2020.104736","journal-title":"Pharmacol Res"},{"key":"951_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil V, Kwon H, Prado P, Hagelkr\u00fcys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Del Pozo CH, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penningeret JM (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181:905\u2013913. https:\/\/doi.org\/10.1016\/j.cell.2020.04.004","journal-title":"Cell"},{"key":"951_CR5","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1097\/HJH.0000000000000321","volume":"32","author":"LA Cal\u00f2","year":"2014","unstructured":"Cal\u00f2 LA, Davis PA, Rossi GP (2014) Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter\u2019s and Gitelman\u2019s syndromes, human models of endogenous angiotensin II signaling antagonism. J Hypertens 32:2109\u20132119. https:\/\/doi.org\/10.1097\/HJH.0000000000000321","journal-title":"J Hypertens"},{"key":"951_CR6","first-page":"472","volume":"23","author":"LA Cal\u00f2","year":"2010","unstructured":"Cal\u00f2 LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D\u2019Angelo A, Pessina AC (2010) ACE2 and angiotensin 1\u20137 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications. J Nephrol 23:472\u2013477","journal-title":"J Nephrol"},{"key":"951_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.23750\/abm.v91i3-S.9511","volume":"91","author":"C Signorelli","year":"2020","unstructured":"Signorelli C, Scognamiglio T, Odone A (2020) COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population. Acta Biomed 91:175\u2013179. https:\/\/doi.org\/10.23750\/abm.v91i3-S.9511","journal-title":"Acta Biomed"},{"key":"951_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1743-422X-2-69","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69. https:\/\/doi.org\/10.1186\/1743-422X-2-69","journal-title":"Virol J"},{"key":"951_CR9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/jmv.25887","volume":"92","author":"A Brufsky","year":"2020","unstructured":"Brufsky A (2020) Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. J Med Virol 92:770\u2013775. https:\/\/doi.org\/10.1002\/jmv.25887","journal-title":"J Med Virol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00951-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-020-00951-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00951-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:31Z","timestamp":1777564531000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/34\/2\/281\/8325941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1007\/s40620-020-00951-6","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"11 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}